Evaluation of the drug–drug interaction potential for trazpiroben (TAK-906), a D₂/D₃ receptor antagonist for gastroparesis, towards cytochrome P450s and transporters

References

• Barski, O.A., Tipparaju, S.M., and Bhatnagar, A., 2008. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug metabolism reviews, 40 (4), 553–624.
   PubMed Web of Science ®Google Scholar
• Bohnert, T., Victim Drug–Drug Interactions Working Group, et al., 2016. Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions-an industry perspective. Drug metabolism and disposition: the biological fate of chemicals, 44 (8), 1399–1423.
   PubMed Web of Science ®Google Scholar
• Chen, C., et al., 2018. Evaluation of the effect of itraconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of a single oral dose of TAK-906, a peripherally-selective D2/D3 dopamine receptor antagonist. United European gastroenterology journal, 8 (1), A501.
   Google Scholar
• Choung, R.S., et al., 2012. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. The American journal of gastroenterology, 107 (1), 82–88.
   PubMed Web of Science ®Google Scholar
• Darmani, N., Zhao, W., and Ahmad, B., 1999. The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). Journal of neural transmission, 106 (11–12), 1045–1061.
   PubMed Web of Science ®Google Scholar
• Duan, P., Zhao, P., and Zhang, L., 2017. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin and atorvastatin to predict drug-drug Interactions (DDIs). European journal of drug metabolism and pharmacokinetics, 42 (4), 689–705.
   PubMed Web of Science ®Google Scholar
• Elsby, R., Hilgendorf, C., and Fenner, K., 2012. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clinical pharmacology and therapeutics, 92 (5), 584–598.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2013). Guideline on the investigation of drug interactions. London, UK: EMA.
   Google Scholar
• Giacomini, K.M., International Transporter Consortium, et al., 2010. Membrane transporters in drug development. Nature reviews drug discovery, 9 (3), 215–236.
   PubMed Web of Science ®Google Scholar
• Harper, T.W., and Brassil, P.J., 2008. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. The AAPS journal, 10 (1), 200–207.
   PubMed Web of Science ®Google Scholar
• Hirano, M., et al., 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. The journal of pharmacology and experimental therapeutics, 311 (1), 139–146.
   PubMed Web of Science ®Google Scholar
• Hoffmann, F., and Maser, E., 2007. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug metabolism reviews, 39 (1), 87–144.
   PubMed Web of Science ®Google Scholar
• Japan Ministry of Health, Labour and Welfare. (2019). Guideline of drug interaction for drug development and appropriate provision of information. Available from: https://www.pmda.go.jp/files/000228122.pdf [accessed 11 October 2020].
   Google Scholar
• Jasper, J.R., and Whiting, R.L., 2020. TAK-906, a dopamine D2/D3 receptor antagonist with minimal brain penetration for gastrointestinal disorders. The FASEB journal, 34 (S1), 1–1.
   Web of Science ®Google Scholar
• Kashyap, P., et al., 2009. The D2/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1] benzopyrano [4,3-b]-1,4-oxazin-9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying. Digestive diseases and sciences, 54 (1), 57–62.
   PubMed Web of Science ®Google Scholar
• Kreckler, L., et al., 2020. Su1739 Safety pharmacology evluations of TAK-906, a novel dopamine D2/D3 selective receptor antagonist for the management of gastroparesis. Gastroenterology, 158 (6), S-627–S-628.
   Web of Science ®Google Scholar
• Lee, A., and Kuo, B., 2010. Metoclopramide in the treatment of diabetic gastroparesis. Expert review of endocrinology and metabolism, 5 (5), 653–652.
   PubMedGoogle Scholar
• Meltzer, H.Y., 2013. Update on typical and atypical antipsychotic drugs. Annual Review of Medicine, 64, 393–406.
   PubMed Web of Science ®Google Scholar
• Michaud, V., and Turgeon, J., 2013. Domperidone and sudden cardiac death: how much longer should we wait? Journal of cardiovascular pharmacology, 61 (3), 215–217.
   PubMed Web of Science ®Google Scholar
• Neuvonen, P.J., Niemi, M., and Backman, J.T., 2006. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics, 80 (6), 565–581.
   PubMed Web of Science ®Google Scholar
• Ramsden, D., et al., 2018. Identification and characterization of a selective human carbonyl reductase 1 substrate. Drug metabolism and disposition, 46 (10), 1434–1440.
   PubMed Web of Science ®Google Scholar
• Romaine, S.P.R., et al., 2010. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. The Pharmacogenomics Journal, 10 (1), 1–11.
   PubMed Web of Science ®Google Scholar
• Rosemond, M.J.C., et al., 2004. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chemico-biological interactions, 147 (2), 129–139.
   PubMed Web of Science ®Google Scholar
• Sanofi-aventis U.S. LLC. 2010. Rifadin (rifampin capsules USP) – FDA reference ID: 2862628. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf [Accessed 27 October 2020].
   Google Scholar
• U.S. Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). (2020). In vitro drug interaction studies – cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for industry. Available from: https://www.fda.gov/media/134582/download [Accessed 11 October 2020].
   Google Scholar
• Varma, M.V., et al., 2012. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharmaceutical research, 29 (10), 2860–2873.
   PubMed Web of Science ®Google Scholar
• Vermeer, L.M., et al., 2016. Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. Drug metabolism and disposition, 44 (3), 453–459.
   PubMed Web of Science ®Google Scholar
• Whiting, R.L., Choppin, A., and Luehr, G., 2020. Su1764 TAK-906, a novel dopamine D2/D3 receptor antagonist for the treatment of gastroparesis. Gastroenterology, 158:S, 638–639.
   PubMed Web of Science ®Google Scholar